Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2008 | 03-2008 | 12-2007 | 09-2007 | 06-2007 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -20,956 | -9,954 | -23,896 | -15,188 | -8,159 |
| Depreciation Amortization | 477 | 228 | 577 | 363 | 210 |
| Accounts receivable | -381 | -351 | -416 | -47 | -32 |
| Other Working Capital | 2,831 | 3,344 | 20,589 | 20,062 | 9,417 |
| Other Operating Activity | 2,320 | 1,223 | 3,000 | 1,837 | 1,089 |
| Operating Cash Flow | $-15,710 | $-5,509 | $-148 | $7,027 | $2,525 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -472 | -205 | -2,365 | -1,332 | -895 |
| Investing Cash Flow | $-472 | $-205 | $-2,365 | $-1,332 | $-895 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 913 | 594 | 56,003 | 55,230 | 54,777 |
| Financing Cash Flow | $913 | $594 | $56,003 | $55,230 | $54,777 |
| Beginning Cash Position | 97,679 | 97,679 | 44,189 | 44,189 | 44,189 |
| End Cash Position | 82,410 | 92,558 | 97,679 | 105,115 | 100,595 |
| Net Cash Flow | $-15,269 | $-5,121 | $53,490 | $60,925 | $56,406 |
| Free Cash Flow | |||||
| Operating Cash Flow | -15,710 | -5,509 | -148 | 7,027 | 2,525 |
| Capital Expenditure | -472 | -205 | -2,365 | -1,332 | -895 |
| Free Cash Flow | -16,182 | -5,714 | -2,513 | 5,695 | 1,629 |